Cupid Limited, a manufacturer and exporter of male condoms, female condoms, water-based lubricants, and In Vitro Diagnostics (IVD) kits, has announced an important board meeting scheduled for January 29, 2026. The meeting will address key financial matters including quarterly results and a potential bonus shares proposal.

Board Meeting Agenda

The board meeting has been convened under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015. The meeting will consider two significant matters for shareholders and investors.

Trading Window Restrictions

Cupid Limited has implemented trading window restrictions in compliance with regulatory requirements. The company notified that the trading window will remain closed for all designated persons, including directors and their immediate relatives, from January 1, 2026, until 48 hours after the financial results for the quarter ended December 31, 2025 are published.

This restriction was communicated through the company's earlier intimation dated December 26, 2025, ensuring compliance with insider trading regulations.

Company Profile

Cupid Limited operates from its factory and registered office located at A-68, M.I.D.C. (Malegaon), Sinnar, Nashik - 422113, Maharashtra, India. The company is incorporated under CIN No.: L25193MH1993PLC070846 and trades on both BSE (Scrip Code: 530843) and NSE (Scrip Code: CUPID).

The formal intimation was signed by Saurabh V. Karmase, Company Secretary and Compliance Officer, on January 9, 2026, and has been communicated to both BSE Limited and The National Stock Exchange of India Ltd for regulatory compliance.

Cupid has delivered exceptional returns over the past year, but recent volatility has left investors questioning whether the remarkable rally can sustain its momentum. The stock's extraordinary performance has been followed by sharp corrections and swift recoveries, creating a complex technical picture that has divided market analysts.

Exceptional Performance Followed by Sharp Correction

The pharmaceutical company's shares have generated multibagger returns that captured significant attention from both retail and institutional investors. The stock's performance across different timeframes demonstrates the magnitude of its rally before the recent turbulence.

The dramatic selloff occurred on January 2, when shares crashed 36% from their peak, followed by a gap-down opening in the subsequent session. However, the stock demonstrated resilience by staging a swift recovery over the following two sessions, supported by strong trading volumes.

Technical Analysis Reveals Mixed Signals

Aakash Shah, Research Analyst at Choice Broking, interprets the recent correction as a short-term profit booking event rather than a breakdown of the broader uptrend. According to Shah, the stock found crucial support near the 50-day EMA and rebounded sharply, indicating sustained buying interest at lower levels.

"The recovery above the 50-day EMA, along with a strong bounce from the 20-day EMA, confirms that the uptrend remains intact. Momentum indicators have reset from overbought zones, which suggests seller exhaustion and scope for stabilisation," Shah explains.

Shah identifies the ₹360–₹350 zone as a strong demand area, with the bullish setup remaining valid as long as the stock holds above this region. He suggests that a sustained move above ₹430–₹440 could trigger a breakout, potentially leading to a retest of the ₹480–₹500 levels.

Cautious Outlook from Alternative Analysis

Jigar S Patel, Senior Manager - Technical Research Analyst at Anand Rathi Shares and Stock Brokers, adopts a more conservative approach to the stock's near-term prospects. Patel emphasizes that the sharp 36% decline from recent highs reflects intense profit-booking pressure and suggests a weakening of the medium-term structure.

"Given the current setup, it is prudent to avoid initiating fresh positions until the stock stabilises," Patel advises, noting that the stock is now trading below its 50-day EMA.

Patel warns that a decisive breakdown below ₹337 could lead to further downside pressure, while identifying ₹410 as a significant resistance level that needs to be overcome for renewed upward momentum.

Market Outlook and Investor Considerations

The contrasting analytical perspectives highlight the complexity of Cupid's current technical setup. While some analysts view the correction as a healthy pause that has reset momentum indicators from overbought levels, others emphasize the need for caution given the stock's position below key moving averages.

Investor attention remains focused on how the stock behaves around critical support and resistance levels in the coming sessions. The company's ability to maintain support above the ₹350–₹360 zone while working toward breaking above ₹410–₹430 resistance will likely determine the next directional move for the stock.